SENTISS
GenericsSENTISS is a generic drug manufacturer focused on Ophthalmology, Cardiovascular, Dermatology.
SENTISS's Key Drugs
SENTISS's core commercial portfolio centers on CIPROFLOXACIN AND DEXAMETHASONE, BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, spanning Ophthalmology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
SENTISS's Recent FDA Approvals
New NDA/BLA approvals for SENTISS over the last two years — novel drugs only, excluding generics and label supplements.
SENTISS's Therapeutic Areas
SENTISS's approved drugs and pipeline span 3 therapeutic areas, led by Ophthalmology and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SENTISS's Top Competitors
SENTISS's closest competitors by therapeutic-area and drug-target overlap include Bayer, B BRAUN, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SENTISS Pipeline Snapshot
Active clinical trials for SENTISS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CIPROFLOXACIN AND DEXAMETHASONE leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Ophthalmology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1996-07-18
- Latest
- 2025-08-27
- Applications
- 11